News

Positive data for HDAC inhibitor - Medivir

Saturday 8 April 2017
Country
Sweden

Sweden-based Medivir AB has reported positive Phase 2 data for a recently acquired histone deacetylase (HDAC) inhibitor in a trial of patients with early-stage cutaneous T cell lymphoma (CTCL), a haematologic cancer that presents in the skin.

Nanobiotix raises €25.1 million in private placement

Friday 7 April 2017
Country
France

Nanobiotix SA, which is developing technology for enhancing radiotherapy treatments, has raised €25.1 million in a private share placement to finance its portfolio and the expected European market launch of its lead product NBTXR3.

Symetis gains access to US market

Friday 7 April 2017
Country
Switzerland

Switzerland-based Symetis GmbH has made a major step onto the US medical device market after agreeing to be acquired by Boston Scientific Corp. The deal, announced on 30 March, consolidates the two companies’ technologies for treating valvular heart disease.

Seed funding for Imperial College spin-out

Thursday 6 April 2017
Country
United Kingdom

Cardian Ltd, a new spin-out from Imperial College London, has received £1.5 million in seed funding to commercialise a device for monitoring patients with heart failure and help physicians manage their care. The device does not need batteries or a power line.

Abzena proposes private share placement

Wednesday 5 April 2017
Country
United Kingdom

UK-based Abzena Plc is proposing to raise about £25 million through a private share placement to finance the expansion of its technology services to companies in the US and Europe. The company is listed on the AIM market, which is part of the London Stock Exchange.

Verona Pharma plans global share offering

Tuesday 4 April 2017
Country
United States

Verona Pharma Plc, which is developing therapeutics for respiratory diseases, has filed registration documents for a public offering of its American Depositary Shares (ADSs) on Nasdaq in New York. UK-based Verona is already listed on the AIM market in London.

EMA reaches out to academia

Tuesday 4 April 2017
Country
United Kingdom

The European Medicines Agency EMA) has formalised its ongoing relationship with universities in order to tap into research that could lead to new medicines and provide regulatory guidance to academic entrepreneurs.

Belgium’s Ogeda to be bought by Astellas

Monday 3 April 2017
Country
Belgium

The privately-owned Belgian drug developer Ogeda SA is to be acquired by Astellas Pharma Inc of Japan in a deal potentially valued at €800 million. Ogeda is developing products for women’s health that target G-protein coupled receptors (GPCRs).

Sirukumab trial results in The Lancet

Sunday 2 April 2017
Country
United States

A Phase 3 trial in which patients with active rheumatoid arthritis (RA) were treated with the monoclonal antibody sirukumab, or placebo, met its primary endpoint of relief from swelling even in those who had failed to respond to two or more biological drugs.

Meeting Report: Opportunities in cell and gene therapy

Saturday 1 April 2017
Country
Spain

The opportunities for commercialising cell and gene therapies appeared relatively bright as the first quarter drew to a close, helped by new finance and the prospective approval of the first cancer products made from engineered T cells.